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1927-321 Effects of DigoXin and Sotalol on Atrial
Defibrillation Thresholds via Implanted
Transvenous Catheter Electrodes
Shinichi Niwano. Mary C. Sokoloski, Jose Ortiz, Celeen Khrestian, Gregory
M. Ayers, Albert L. Waldo. Case Western Reserve University, Cleveland. OH
Digoxin Voltage IV) Energy (J) Impedance (a) %Success (%)
Drug free 85 ± 21 0.27±015 40 ± 7 40 ± 17
Therapeutic dose 77 ± 29 0.28±018 36 ± 3 30 ± 19
Toxic dose 77 ± 29 029 ± 0.16 36± 8 42 ± 16
Sotalol
Drug free 64 ± 5 013 ± 004 45 ± 7 30 ± 23
Sotalol 52 ± 8' 0.10 ± 003 44± 7 29 ± 18
'p < 005
Maturation of an Atrial Defibrillation Lead System
Causes No Change in Threshold
Gregory M. Ayers, Xavier Gonzalez, Marina B. Ilina, Darrell O. Wagner, William
A. Sirokman, Clil A. Alferness. InControl Inc. Redmond, WA
Objectives It has been documented in animal models that a synchronized
shock delivered to the atria through transvenous catheter electrodes is a fea-
sible method to terminate atrial fibrillation (AF). Because digoxin and sotalol
are frequently used in the management of patients with AF, we studied the
effect of these drugs on atrial defibrillation thresholds (ADFTs).
Methods Sterile pericarditis was created using standard methods in 17
mongrel dogs. Two catheter electrodes with a 6 cm coil tip were inserted
through the right external jugular vein and placed in the distal coronary si-
nus and in the right atrial appendage, respectively. They were subsequently
used for delivery of atrial shocks. On the second postoperative day, AF was
induced by rapid atrial pacing, and ADFT was determined in the drug free
state and after administration of 1) a therapeutic dose of digoxin (50 JLg/kg;
6 dogs); 21 a toxic dose of digoxin (increased dose, mean 106 JLg!kg, asso-
ciated with a digitalis toxic rhythm; 6 dogs); or 3) sotalol (1 mg!kg followed
by a continuous infusion of 0.375 mg!kglhr; 5 dogs). ADFT was determined
in a 10 V step-up manner, with 20 shocks delivered at the lowest intensity
that converted AF to determine % success. ADFT was defined as the lowest
defibrillation energy which achieved successful atrial defibrillation between
10% and 90% of the time.
Results Data are shown in mean ± SD.
Digoxin did not significantly affect the voltage, energy, or impedance of the
shock, butsotalol significantly decreased the mean ADFT voltage required.
Conclusions In the sterile pericarditis model of AF: 1) ADFT was very low
1<03 J) through transvenous catheter electrodes; and 2) digoxin did not sig-
nificantly affect ADFTs, although sotalol decreased ADFTs determined using
transvenous catheter electrodes.
Previous work in transvenous ventricular defibrillation has shown changes in
defibrillation requirements during lead maturation. We evaluated the changes
in atrial defibrillation thresholds for a three lead transvenous system over a
three month period.
In 8 adult sheep (60 ± 10 kg at implant). a three-lead atrial defibrillation sys-
tem was implanted. Two custom built atrial defibrillation leads, each with a
6 cm distal shocking coil, were positioned. one in the great cardiac vein and
one in the right atrium. A bipolar pacing lead was positioned at the right ven-
tricular apex for shock synchronization. Leads were connected to datablocks
which were inserted into subcutaneous pockets. Custom insulated needles
were inserted through the skin and into the datablocks to establish electri-
cal contact with the leads. If atrial fibrillation was stable, an atrial defibrillation
threshold (ADFT)was obtained at implant and at follow-up studies 2, 4, 8, and
12 weeks after implant. ADFTs were obtained in a 1OV step-up manner as pre-
viously described by our group. The ADFTs from animals with stable AF IN) for
each follow-up interval are shown in the table below. Values are mean ± 1 sd.
Background; Transvenous atrial defibrillation IADF) is a recently developing
technique for converting atrial fibrillation (AF) to sinus rhythm. Adjunctive an-
tiarrhythmic therapy is likely to be used to maintain sinus rhythm.
Aim; To evaluate the effects of sotalol on transvenous ADF for AF.
Methods; R wave synchronized, biphasic (3 ms + 3 ms), truncated ex-
ponential shocks were delivered between decapolar catheters in the right
atrium and the coronary sinus at increasing voltages Ibetween 20V to 380V, in
steps of 40VI until sinus rhythm returned or maximum voltage achieved. Sus-
tained AF was reinduced with atrial pacing, intravenous sotalol (1.5 mg/kg)
was given and ADF was repeated.
Patients; Twenty one patients with chronic AF (mean duration of 15 ± 16
monthsl and 11 patients with AF induced during electrophysiologic study un-
derwent ADF. The mean age was 49 ± 8 years, 56 ± 9 years and left atrial
diameter was 3.5 ± 0.5 cm, 4.0 ± 0.6 cm (p = 0.01) for acute and chronic AF,
respectively.
Results; All except 3 and 2 patients were successfully cardioverted at base-
line and after sotalol infusion, respectively. Sotalol maintained sinus rhythm
in 4 patients in whom AF recurred within lOs after successful defibrillation at
baseline.
in 7 patients, syncope in 6 pts and ventricular fibrillation (VF) in 9 patients.
Each patient underwent programmed ventricular stimulation on no antiar-
rhythmic drug therapy prior to implantation; 20 patients had uniform VT in-
duced (range of 1-5 different VTs induced per patientl. The mean induced VT
cycle length was 361 ± 53 ms for the 7 pts presenting with tolerated VT and
272 ± 58 ms forthe 13 patients presenting with syncope or VF (p < 0.05). The
shortest induced tachycardia cycle length was 346 ± 43 is for patients pre-
senting with tolerated VT and 257 ± 57 ms for patients presenting with syn-
cope or VF (p < 0.05). For analysis of recurrences, only electrogram record-
ings on which the initiation of the spontaneous arrhythmia could be seen
were utilized. Results; The mean followup was 26 ± 21 months (range 1 to
67 months). The number of VT recurrences per patient was 2.6 ± 2.9 (range 1
to 14). No patient had an RCL shorter than the shortest induced cycle length.
The mean RCL was 333 ± 74 ms for patients presenting with tolerated VT and
318 ± 63 ms for patients presenting with syncope or VF (p = 0.7). The short-
est RCL was 313 ± 70 ms for patients presenting with tolerated VT and 305 ±
75 ms for patients presenting with syncope or VF (p = 0.8). Each of the RCLs
in patients presenting with tolerated VT was within 75 milliseconds of both
the cycle length at presentation and at least 1 of their induced tachycardia cy-
cle lengths. However, among patients presenting with syncope or VF, 5133%)
had an RCL on at least 1 occasion which was> 100 ms longer than any cy-
cle length induced at programmed stimulation. Conclusions; Clinical presen-
tation is more closely associated with induced than with recurrent VT cycle
length. Patients with a clinical presentation of tolerated VT had RCLs simi-
lar to both the tachycardia cycle length at presentation and the cycle length
of one or more tachycardias induced with programmed stimulation. Patients
presenting with syncope or VF commonly had recurrences with cycle lengths
much longer than any induced at programmed stimulation. These data may
have implications for device selection and programming.
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Effect of Sotalol on Transvenous Atrial
Defibrillation for Acute and Chronic Atrial
Fibrillation
Lok Ngai Sang, Lau Chu Pak, Tang Yuen Wai, Ho Sai Wah. David. Div of Cardiology,
Dept. of Medicine, University of Hong Kong, Queen Mmy Hospital, Hong Kong
Internal Atrial Defibrillation
Acute AF Before Sotalol After sotalol P value
Energy (J) 2.6 ± 1.7 1.9 ± 1.5 0.05
Post-shock RR (ms) 1479 ± 1031 2647 ± 2106 007
Mean pressure (mmHg) 90 ± 16 80 ± 11 003
Chronic AF Before Sotalol After Sotalol P value
Energy (J) 3.6 ± 1.4 3.1 ± 1.2 0.34
Post-shock RR Ims) 2291 ± 1432 3160 ± 1706 013
Mean pressure (mmHg) 104 ± 23 91 ± 28 016
Conclusion; Transvenous ADF was effective in restoring sinus rhythm for
both acute and chronic AF, sotalollowered the defibrillation energy and may
have important implications in reducing pain sensation and maintaining sinus
rhythm during ADF. Transvenous ADF was more effective in restoring sinus
rhythm in acute AF than in chronic AF (1 00% vs 85.7%, p < 0.001), and was
achieved at a lower defibrillation energy.
N ADFT-V ADFT-E Impedance
Implant 5 138±40V 07 ± 0.4 J 56 ± 7 a
2Wk 6 125 ± 37 V 06 ± 0.5 J 51 ± 4 a
4Wk 6 125±41V 06 ± O.4J 52 ± 3 a
8Wk 5 112±29V 0.5 ± 0.2 J 61 ± 7 a
12Wk 7 145±53V 0.8 ± 06 J 63± 8n
There was no significant difference in the ADFT voltage or energy over the
three month follow-up period (p > 0.05). Lead impedance was not signifi-
cantly different for any of the follow-up intervals as compared to implant (p
> 0.05) however weeks 2 and 4 were significantly lower than weeks 8 and
12 (p < 0.05) Conclusions; Unlike ventricular defibrillation thresholds from
transvenous leads, atrial defibrillation thresholds from transvenous leads do
not significantly change overthe three months after implant.
